ERBB2 and endometrial serous adenocarcinoma: On the other hand, in a phase II randomized trial of HER2-positive advanced or recurrent uterine serous carcinomas, patients were randomized into a trastuzumab-plus-carboplatin-and-paclitaxel (T arm) or carboplatin-and-paclitaxel group (C arm) [80].